galexos capsule
janssen inc - simeprevir (simeprevir sodium) - capsule - 150mg - simeprevir (simeprevir sodium) 150mg - hcv protease inhibitors
olysio simeprevir capsule
janssen products lp - simeprevir (unii: 9ws5rd66hz) (simeprevir - unii:9ws5rd66hz) - simeprevir 150 mg
olysio
janssen-cilag international nv - simeprevir - hepatitis c, chronic - antivirals for systemic use - olysio is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adult patients.for hepatitis c virus (hcv) genotype specific activity.
olysio
janssen-cilag (new zealand) ltd - simeprevir sodium 154.4mg equivalent to simeprevir 150.0 mg - capsule - 150 mg - active: simeprevir sodium 154.4mg equivalent to simeprevir 150.0 mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin lactose monohydrate magnesium stearate opacode black s-1-277002 sodium laurilsulfate - olysio is indicated for the treatment of chronic hepatitis c (chc) genotype 1 or genotype 4 infection, in combination with other medicinal products for the treatment of chc infection.
olysio 150mg capsules
janssen-cilag ltd - simeprevir sodium - capsule - 150mg
stocrin 600 mg tablets
merck sharp & dohme (israel - 1996) company ltd, israel - efavirenz - film coated tablets - efavirenz 600 mg - efavirenz - efavirenz - stocrin in combination with other antiretroviral agents, is indicated for the treatment of hiv-1-infection .
olysio hard capsules 150 mg
wael pharmacy - simeprevir - hard capsules - 150
olysio 150mg capsule
johnson & johnson (phils.) inc.; distributor: johnson & johnson (phils.) inc. - simeprevir - capsule - 150mg
olysio 150mg capsule
janssen-cilag - simeprevir - capsule - 150 mg
efavirenz/emtricitabine/tenofovir disoproxil zentiva
zentiva k.s. - efavirenz, emtricitabine, tenofovir disoproxil, phosphate - hiv infections - antivirals for systemic use, - efavirenz/emtricitabine/tenofovir disoproxil zentiva is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. it is indicated for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adults aged 18 years and over with virologic suppression to hiv-1 rna levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in efavirenz/emtricitabine/tenofovir disoproxil zentiva prior to initiation of their first antiretroviral treatment regimen., the demonstration of the benefit of the combination efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavir